Why Eli Lilly's Profits Aren't a Sure Thing for Marketers Despite Obesity Drug Push
Eli Lilly appears to be making as many of its popular obesity and diabetes drugs as possible, but shortages are…
investment strategy
Unjustified drop after GEHC results is a buying opportunity
Every weekday, the CNBC Investing Club with Jim Cramer publishes Homestretch, a helpful afternoon update just in time for the…
Eli Lilly (LLY) Says It Can Overcome the Problem of Too Much Demand for High Quality
Eli Lilly's improved guidance stole the show on Tuesday, offsetting mixed first-quarter results and sending shares up nearly 6%. The…
Citigroup CEO Jane Fraser says low-income consumers are more cautious
citi group Chief Executive Jane Fraser said Monday that consumer behavior has diverged as inflation of goods and services makes…
Berkshire Hathaway's Big Mystery Stock Bet Could Be Revealed Soon
Warren Buffett walks the grounds at the Berkshire Hathaway Annual Shareholders Meeting in Omaha Nebraska. David A. Grogan | CNBC…
The promise of Eli Lilly's weight-loss drug for sleep apnea adds reasons to own it
Eli Lilly's weight-loss drug Zepbound showed promise as a treatment for sleep apnea, giving investors more confidence to continue owning…
JPMorgan Chase (JPM) earnings in the first quarter of 2024
JPMorgan Chase on Friday posted earnings and revenue that beat Wall Street estimates as credit costs and trading revenue came…
Citigroup (C) earnings first quarter of 2024
citi group on Friday reported first-quarter revenue that topped analyst estimates, helped by better-than-expected results in the bank's trading and…
Biotech stocks are ready to break out. They just need one more thing
As debate continues over when the Federal Reserve might begin cutting interest rates, biotech industry analysts argue that the case…
We're buying more shares of this healthcare company amid an overblown sell-off
Shortly after the opening bell, we will purchase 140 shares of Abbott Laboratories at approximately $112. Following the deal, Jim…